title: [Use of peg-intron in combined treatment of chronic liver disease caused by HIV infection].
abstract: The efficiency of treatment of patients with chronic hepatitis type C and liver cirrhosis of HCV etiology with PegIntron in conjunction with Ribavirin made up 73.3% in the group of patients with different HCV genotypes. Due to the development of side effects, it was possible to perform the complete course of treatment only in 30 patients out of 34 (88.2%). Side effects from the side of the central nervous system (irritability, depressive syndrome, sleep disorders), skin (xerodermia, alopecia, seborrhea), and weight loss prevailed against the background of combined treatment with PegIntron and Ribavirin. Upon the completion of treatment, side effects disappeared in 31 patients out of 34 (91.2%) within 1-3 months.
authors.forename: N I
authors.initials: NI
authors.lastname: Pomova
authors.forename: I O
authors.initials: IO
authors.lastname: Ivanikov
authors.forename: V E
authors.initials: VE
authors.lastname: Siutkin
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications*; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a